[1] [1] Y. Wang, Y. Gu, "Advances in clinical application and study on tumor-targeted photodynamic therapy," Chin. J. Laser Med. Surg. 26, 279–287 (2017).

[2] [2] T. J. Dougherty, C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan, Q. Peng, "Photodynamic therapy," J. Natl. Cancer Inst. 90, 889–905 (1998).

[3] [3] Z. Huang, B. C. Wilson, "Advances in photodynamic therapy dosimetry," Prog. Biochem. Biophys. 36, 676–683 (2009).

[4] [4] A. D. Garg, P. Agostinis, "ER stress, autophagy and immunogenic cell death in photodynamic therapyinduced anti-cancer immune responses," Photochem. Photobiol. Sci. 13, 474–487 (2014).

[5] [5] A. D. Garg, A. M. Dudek, P. Agostinis, "Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?" Biofactors 39, 355–367 (2013).

[6] [6] A. D. Garg, D. V. Krysko, P. Vandenabeele, P. Agostinis, "Author correction: Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin," Cancer Immunol. Immunother. 67, 215–221 (2018).

[7] [7] A. D. Garg, D. V. Krysko, P. Vandenabeele, P. Agostinis, "DAMPs and PDT-mediated photooxidative stress: Exploring the unknown," Photochem. Photobiol. Sci. 10, 670–680 (2011).

[8] [8] D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, P. Vandenabeele, "Immunogenic cell death and DAMPs in cancer therapy," Nat. Rev. Cancer 12, 860–875 (2012).

[9] [9] P. Mroz, A. Szokalska, M. X. Wu, M. R. Hamblin, "Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response," PLoS One 5, 1–11 (2010).

[10] [10] I. Martins, O. Kepp, L. Galluzzi, L. Senovilla, F. Schlemmer, S. Adjemian, L. Menger, M. Michaud, L. Zitvogel, G. Kroemer, "Surface-exposed calreticulin in the interaction between dying cells and phagocytes," Ann. N. Y. Acad. Sci. 1209, 77–82 (2010).

[11] [11] L. Chen, D. B. Flies, "Molecular mechanisms of T cell co-stimulation and co-inhibition," Nat. Rev. Immunol. 13, 227–242 (2013).

[12] [12] J. H. Esensten, Y. A. Helou, G. Chopra, A. Weiss, J. A. Bluestone, "CD28 Costimulation: From mechanism to therapy," Immunity 44, 973–988 (2016).

[13] [13] C. Dong, A. E. Juedes, U. A. Temann, S. Shresta, J. P. Allison, N. H. Ruddle, R. A. Flavell, "ICOS costimulatory receptor is essential for T-cell activation and function," Nature 409, 97–101 (2001).

[14] [14] M. Croft, "The role of TNF superfamily members in T-cell function and diseases," Nat. Rev. Immunol. 9, 272–285 (2009).

[15] [15] Z. Tao, T. D. Li, Z. X. Liu, Y. Chen, H. Y. Yang, "Clinic study of the HpD-laser for the diagnosis and treatment of neoplasm," J. Bengbu Med. Coll. 19, 29–31 (1994).

[16] [16] P. Mroz, J. T. Hashmi, Y. Y. Huang, N. Lange, M. R. Hamblin, "Stimulation of anti-tumor immunity by photodynamic therapy," Expert Rev. Clin. Immunol. 7, 75–91 (2011).

[17] [17] G. Canti, D. Lattuada, A. Nicolin, P. Taroni, G. Valentini, R. Cubeddu, "Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light," Anticancer Drugs 5, 443–447 (1994).

[18] [18] M. Korbelik, G. Krosl, J. Krosl, G. J. Dougherty, "The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy," Cancer Res. 56, 5647–5652 (1996).

[19] [19] M. Korbelik, G. J. Dougherty, "Photodynamic therapy-mediated immune response against subcutaneous mouse tumors," Cancer Res. 59, 1941–1946 (1999).

[20] [20] P. S. Thong, M. Olivo, K. W. Kho, R. Bhuvaneswari, W. W. Chin, K. W. Ong, K. C. Soo, "Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy," J Environ Pathol Toxicol Oncol 27, 43–50 (2008).

[21] [21] Y. X. Chen, Effects of photodynamic therapy on immune function of G422 intracranial tumor- bearing mice, The 9th Acad. Conf. Neurosurgery Branch of the Chinese Medical Association (2010).

[22] [22] M. Shams, B. Owczarczak, P. Manderscheid-Kern, D. A. Bellnier, S. O. Gollnick, "Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease," Cancer Immunol. Immunother. 64, 287–297 (2015).

[23] [23] B. W. Henderson, S. O. Gollnick, J. W. Snyder, T. M. Busch, P. C. Kousis, R. T. Cheney, J. Morgan, "Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors," Cancer Res. 64, 2120–2126 (2004).

[24] [24] F. Zhou, D. Xing, W. R. Chen, "Regulation of HSP70 on activating macrophages using PDT-induced apoptotic cells," Int. J. Cancer 125, 1380–1389 (2009).

[25] [25] M. C. Rodrigues, W. T. de Sousa Júnior, T. Mundim, C. L. C. Vale, J. V. de Oliveira, R. Ganassin, T. J. A. Pacheco, J. A. Vasconcelos Morais, J. P. F. Longo, R. B. Azevedo, L. A. Muehlmann, "Induction of immunogenic cell death by photodynamic therapy mediated by aluminumphthalocyanine in nanoemulsion," Pharmaceutics 14, 1–13 (2022).

[26] [26] X. Wang, J. Ji, H. Zhang, Z. Fan, L. Zhang, L. Shi, F. Zhou, W. R. Chen, H. Wang, X. Wang, "Stimulation of dendritic cells by DAMPs in ALAPDT treated SCC tumor cells," Oncotarget 6, 44688–44702 (2015).

[27] [27] A. D. Garg, D. V. Krysko, T. Verfaillie, A. Kaczmarek, G. B. Ferreira, T. Marysael, N. Rubio, M. Firczuk, "A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death," Embo J. 31, 1062–1079 (2012).

[28] [28] M. Korbelik, W. Zhang, S. Merchant, "Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: Surface expression of calreticulin and high-mobility group box-1 release," Cancer Immunol. Immunother. 60, 1431–1437 (2011).

[29] [29] E. Panzarini, V. Inguscio, G. M. Fimia, L. Dini, "Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of damage-associated molecular patterns (DAMPs) in human HeLa cells," PLoS One 9, 1–12 (2014).

[30] [30] N. Trempolec, B. Doix, C. Degavre, "Photodynamic therapy-based dendritic cell vaccination suited to treat peritoneal mesothelioma," Cancers 12, 1–16 (2020).

[31] [31] R. Spisek, M. V. Dhodapkar, "Towards a better way to die with chemotherapy: Role of heat shock protein exposure on dying tumor cells," Cell Cycle 6, 1962–1965 (2007).

[32] [32] V. D. Turubanova, I. V. Balalaeva, T. A. Mishchenko, E. Catanzaro, R. Alzeibak, N. N. Peskova, I. Efimova, "Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine," J. Immunother. Cancer 7, 819–826 (2019).

[33] [33] A. D. Garg, L. Vandenberk, C. Koks, T. Verschuere, L. Boon, S. W. Van Gool, P. Agostinis, "Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of highgrade glioma," Sci. Transl. Med. 8, 1–15 (2016).

[34] [34] R. Djukanovic, "The role of co-stimulation in airway inflammation," Clin. Exp. Allergy. 30, 46–50 (2000).

[35] [35] Y. Choi, Y. Shi, C. L. Haymaker, A. Naing, G. Ciliberto, J. Hajjar, "T-cell agonists in cancer immunotherapy," J. Immunother. Cancer 8, 1–14 (2020).

[36] [36] J. Song, S. Salek-Ardakani, P. R. Rogers, M. Cheng, L. Van Parijs, M. Croft, "The costimulationregulated duration of PKB activation controls T cell longevity," Nat. Immunol. 5, 150–158 (2004).

[37] [37] R. G. Jones, S. D. Saibil, J. M. Pun, A. R. Elford, M. Bonnard, M. Pellegrini, S. Arya, M. E. Parsons, "NF-kappaB couples protein kinase B/Akt signaling to distinct survival pathways and the regulation of lymphocyte homeostasis in vivo," J. Immunol. 175, 3790–3799 (2005).

[38] [38] D. S. Chen, I. Mellman, "Oncology meets immunology: The cancer-immunity cycle," Immunity 39, 1–10 (2013).